Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProMIS NeurosciencesPMN +3.57%35 3-Year EBITDA Growth Rate is 27.50% as of Jun. 2026, which is 126% above its 10-year median of 12.15. GuruFocus rates PMN with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,130 Biotechnology companies, ProMIS Neurosciences ranks better than 63.63% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 27.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of ProMIS Neurosciences was 34.10% per year. The lowest was -30.90% per year. And the median was 12.15% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
ProMIS Neurosciences 3-Year EBITDA Growth Rate Related Terms
PMN vs FBIO, VANI, SEER: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, ProMIS Neurosciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProMIS Neurosciences 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where ProMIS Neurosciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 27.50% mean?
ProMIS Neurosciences (PMN) has a 3-Year EBITDA Growth Rate of 27.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ProMIS Neurosciences and its competitors. This is 126% above median its historical median of 12.15. According to the industry distribution chart, ProMIS Neurosciences ranks #411 out of 1130 companies in the Biotechnology industry, placing it in the top 36.4%.
Is ProMIS Neurosciences' 3-Year EBITDA Growth Rate too high?
ProMIS Neurosciences' current 3-Year EBITDA Growth Rate of 27.50% is 126% above median its 10-year median of 12.15. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. ProMIS Neurosciences' value of 27.50% is 85.2% above this industry median. Based on the distribution chart, ProMIS Neurosciences ranks #411 out of 1130 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ProMIS Neurosciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' 3-Year EBITDA Growth Rate compare to FBIO and VANI?
According to the Biotechnology industry distribution chart, ProMIS Neurosciences ranks #411 out of 1130 companies for 3-Year EBITDA Growth Rate. This puts ProMIS Neurosciences in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. ProMIS Neurosciences' value of 27.50% is 85.2% above this benchmark. While the company's 10-year median is 12.15 vs. the industry median of 14.85, ProMIS Neurosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProMIS Neurosciences's current 3-Year EBITDA Growth Rate of 27.50% is 85.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ProMIS Neurosciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProMIS Neurosciences's current 3-Year EBITDA Growth Rate is 27.50%, which is 126% above median its own 10-year median of 12.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current 3-Year EBITDA Growth Rate of 27.50%. The current 3-Year EBITDA Growth Rate is 27.50%, which is 126% above median its 10-year median of 12.15 and 85.2% above the Biotechnology industry median of 14.85. ProMIS Neurosciences' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current 3-Year EBITDA Growth Rate is 27.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
35GF Score
Get the complete analysis for PMN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMN has been successfully added to your 
